Thus, these results suggest that inhibition of EGFR signaling cascade is still beneficial to antitumor effects in KRAS mutant-driven tumorigenesis and EGFR-targeted drugs such as cetuximab and panitumumab can be used as crucial therapeutic options for treating a subset of cancer patients harboring KRAS activating mutations. Here, KRAS is linked to cancer.